New research out of the University of Texas Medical Branch potentially points to an effective treatment for Lassa fever, a dangerous, often fatal disease common to much of West Africa but considered a major threat to global health.
CEPI, the Coalition for Epidemic Preparedness Innovations, and the Houston Methodist Research Institute (HMRI), have today announced a partnership to combine cutting-edge artificial intelligence (AI) technology with established laboratory techniques to speed up development of future vaccines against novel viral threats (also known as Disease X).
It is a remarkable thing to read. Hop into the wayback machine and park it in front of this article that appeared as part of a China series in The New York Times Magazine on November 18, 2018. The author is Philip P. Pan, he the Asia editor of The New York Times. The title of the piece?
Scientists have developed a novel Lassa vaccine using a recombinant measles virus and tested its protective efficacy against Lassa fever. A single vaccine dose has been found to induce a rapid and robust immune response in monkeys with pre-existing immunity against the measles virus.